Galectin-1 / TLR4 / NF-κB monocyte inflammation axis in MPN
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-23 — Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms.: Primary study establishes LGALS1 enrichment in MPN monocytes and demonstrates that galectin-1 drives monocyte hyperinflammation via TLR4–NF-κB signaling, with genetic/pharmacologic inhibition reducing splenomegaly, leukocytosis, and thrombosis in the MPLW515L mouse model (scRNA-seq, CyTOF, in vitro assays, in vivo knockout). (novelty: 5)